Experts Re-evaluate Older Weight-Loss Drug Amid Popularity of Newer Options
While medications like Wegovy and Mounjaro gain attention, an older, less expensive pill shows promise for specific eating behaviors.
A weight-loss drug that has been overshadowed by newer, more popular medications like Wegovy and Mounjaro is gaining renewed attention from experts. While the newer drugs, often associated with celebrity endorsements, continue to capture public interest, some specialists believe an older medication offers significant benefits, particularly for individuals struggling with binge eating or persistent cravings.
This re-evaluation focuses on a drug that is potentially more affordable and may be particularly effective for specific types of weight-related challenges. Unlike the newer GLP-1 agonists which mimic a natural hormone released after eating to signal fullness, this older drug approaches weight management through a different mechanism.
In clinical trials, participants using certain weight-loss medications, such as Contrave (which contains naltrexone and bupropion), have shown notable results. While the percentage of weight lost might be lower than that achieved with the latest GLP-1s, these older medications can be a valuable tool, especially for those whose weight gain is linked to specific behavioral patterns like binge eating or intense cravings. The effectiveness for these particular issues is a key factor driving renewed interest.
The discussion around weight-loss treatments has often centered on the high-profile drugs that have become household names. However, this expert perspective suggests a more nuanced approach, highlighting that a "forgotten" drug could offer a cost-effective and targeted solution for a segment of the population seeking to manage their weight.